Further explorations of surveillance data: case detection (all cases vs. bacteriologically confirmed, All strategies) Good afternoon. I will give a brief.

Slides:



Advertisements
Similar presentations
Clinical pathology: SEROMARKER FOR TB
Advertisements

Agenda Background Current testings Xpert MTB/RIF product PAGE | 1.
BACKGROUND LOW INCOME COUNTRY TUBERCULOSIS ♂>♀ A I M 1.Identify gender based differences in patients with Pulmonary Tb 2. Use this information to improve.
Overview of current case and treatment outcome definitions Malgosia Grzemska TB Operations and Coordination Stop TB Department Consultation Impact of WHO-endorsed.
World Health Organization TB Case Definitions
MDCH STATE LABORATORY TUBERCULOSIS TESTING Specimens/Tests/Reports
Nucleic Acid Amplification Test for Tuberculosis
World Tuberculosis Day 2015 The TB situation in 2013: Findings from the joint TB surveillance and monitoring report by ECDC and the WHO Regional Office.
Monitoring and Evaluation: A Review of Terms. Goals To provide better treatment for people with tuberculosis in Country X To achieve a treatment success.
Molecular Diagnosis of Infectious Diseases. Why use a molecular test to diagnose an infectious disease? Need an accurate and timely diagnosis Important.
World Tuberculosis Day 2014 The TB situation in 2012: Findings from the joint TB surveillance and monitoring report by ECDC and the WHO Regional Office.
World Tuberculosis Day 2014 The TB situation in 2012: Findings from the joint TB surveillance and monitoring report by ECDC and the WHO Regional Office.
Diagnosis of TB.
Tuberculosis in the UK 2013 report
Tuberculosis in the UK 2014 report
Indiana CTSI ACCELERATING CLINICAL AND TRANSLATIONAL RESEARCH Indiana C linical and T ranslational S ciences I nstitute Mycobacterium.
1 Epidemiology of Pediatric Tuberculosis in the United States, 1993–2006 Surveillance, Epidemiology, and Outbreak Investigations Branch Division of Tuberculosis.
1 Tuberculosis: Basics Rick Speare Anton Breinl Centre School of Public Health, Tropical Medicine and Rehabilitation Sciences James Cook University 16.
DEPARTMENT OF HEALTH DOTS Program for TB (Tuberculosis Directly Observed Short-course)
FIND Ongoing Activities What’s in the pipeline for Rapid DST? WHO Stop TB Department Supranational Reference Laboratory Network Meeting Paris, October.
Introduction to Tuberculosis Genotyping National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division of Tuberculosis Elimination.
Screening for TB.
Universal access to TB care what is the challenge, what policy, what is being implemented Cancun 3 December 2009 Léopold BLANC and TBS team TBS/STB/WHO.
Preparing for Cohort Review & Standard Forms for Cohort Presentation June 16, 2010 Kieran Hartsough.
Health Organization The Challenges Facing Tuberculosis Control Blantyre Hospital, Malawi: TB Division, 3 patients per bed.
Module 2 TB Disease Transmission & Prevention. Pulmonary Tuberculosis Extra -Pulmonary TB an infectious disease caused by a microorganism called Mycobacterium.
Harvard University Initiative for Global Health Global Health Challenges Social Analysis 76: Lecture 8.
Surveillance, Epidemiology, and Outbreak Investigations Branch Division of Tuberculosis Elimination Centers for Disease Control and Prevention (CDC) Epidemiology.
Observing Microorganisms through a Microscope
INSTITUTO DE INFECTOLOGIA EMÍLIO RIBAS Identification of Mycobacterium tuberculosis complex in clinical specimens of HIV-infected patients at Instituto.
World Tuberculosis Day 2016 Monitoring the implementation of the Framework Action Plan to Fight Tuberculosis in the European Union – Situation in 2014.
Monitoring and Evaluation: A Review of Terms
TUBERCULOSIS IN JAPAN ANNUAL REPORT – 2016.
World Tuberculosis Day 2014
Figure 1. Trends of positive-to-negative culture conversion assessed by weekly serial induced sputum after adequate standard anti-tuberculosis medication.
This is an archived document.
World Tuberculosis Day 2013
Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV- associated pulmonary tuberculosis before antiretroviral therapy:
World Tuberculosis Day 2014
Fifth Pacific Stop TB meeting Fiji Islands, May 4-7, 2010
This is an archived document.
Nucleic Acid Amplification Test for Tuberculosis
PAEDIATRIC TUBERCULOSIS MAY STILL BE UNDER DIAGNOSED AND UNDER TREATED

PROGRESS IN GLOBAL TB CONTROL
World Tuberculosis Day 2015
Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV- associated pulmonary tuberculosis before antiretroviral therapy:
Presentation 10 Analysing results and defining cases
Monitoring the implementation of the TB Action Plan for the WHO European Region, 2016–2020 EU/EEA situation in 2016 ECDC Tuberculosis Programme European.
بسم الله الرحمن الرحيم.
Tuberculosis situation in the EU/EEA, 2016
World Tuberculosis Day 2014
World Tuberculosis Day 2016
World Tuberculosis Day 2014
Observing Microorganisms through a Microscope
Tb: Screening & Diagnosis (1)
Tuberculosis in Wales Annual Report 2018 Data to the end of 2017
Deciphering TB Lab Reports
DOTS IMPACT TO TUBERCULOSIS IN LITHUANIA
Surveillance of Tuberculosis
PROGRESS IN GLOBAL TB CONTROL
Communicable Disease Surveillance Centre, London
Using Whole Genome Sequencing Analysis in California
Tuberculosis situation in the EU/EEA, 2017
Laura Lane, Epidemiologist
Tuberculosis situation in the EU/EEA, 2017
Surveillance: From Patient to CDC
Tuberculosis in Wales Annual Report 2017 Data to the end of 2016
Tuberculosis situation in the EU/EEA, 2017
Basic diagnostic algorithm to link the molecular line probe assay with solid culture- and liquid culture-based growth detection and susceptibility testing.
Presentation transcript:

Further explorations of surveillance data: case detection (all cases vs. bacteriologically confirmed, All strategies) Good afternoon. I will give a brief overview (Next slide) Chris Dye and Jerod Scholten Tuberculosis Control World Health Organization

Why is acid fast bacilli smear an important tool for a TB programme? Allows quick identification of TB cases Inexpensive and low tech Identifies potentially infectious cases Permits a programme to identify and treat patients who can infect others Disadvantage: the AFB smear cannot distinguish non-TB from TB mycobacterium

New, pulmonary, smear-positive TB case detection rates*, 2001** SS+ detection rates (%) < 50 51-69 ≥ 70 * Notified/estimated ** 2000 data for KRG and UKR

Should we use culture in Europe as an indicator of case detection? Culture is the gold standard of TB confirmation Permits identification of mycobacterium species and drug susceptibility (as well as DNA fingerprinting) Not all pulmonary patients who are culture positive will be smear positive Do we miss more infectious patients by focusing on culture? Disadvantages: higher costs, higher tech, slow growing Should this be used selectively in developing countries? Universally in wealthy countries?

Reported laboratory confirmation of new pulmonary TB cases, 2001 Proportion of smear and/or culture confirmed new pulmonary cases < 50% 50-64% ≥ 65% Unknown